Financial Data and Key Metrics Changes - For Q1 2025, the company reported a net loss of approximately $8.5 million, or about $0.21 per share, compared to a net loss of $10.6 million, or $0.30 per share, in Q1 2024, reflecting a decrease due to increased tax benefits and lower operating expenses [12][13] - Research and development expenses were $5.8 million for Q1 2025, down from $6.7 million in the prior year, primarily due to lower clinical trial expenses [12] - General and administrative expenses were $3.3 million for Q1 2025, compared to $3.4 million in the prior year [13] - Total operating expenses decreased to $9.1 million in Q1 2025 from approximately $10.1 million in Q1 2024 [13] - Cash balance as of March 31, 2025, was $40 million, down from $41.7 million as of December 31, 2024 [13] Business Line Data and Key Metrics Changes - The company initiated the VERSAL-three registrational trial for Versamune HPV plus pembrolizumab, targeting recurrent or metastatic HPV16 positive head and neck cancer, which is projected to become the most prevalent type of head and neck cancer by the mid-2030s [6][8] - The VERSAL-three trial design includes approximately 350 patients, with a two-arm design approved by the FDA [7] Market Data and Key Metrics Changes - The company highlighted the growing population in need of targeted therapies for HPV16 positive head and neck cancer, which is difficult to treat and represents a significant market opportunity [5][6] Company Strategy and Development Direction - The company is focused on advancing its clinical programs, particularly the VERSAL-three trial, which is the first phase three trial in the high-risk HPV16 population [8][54] - The company aims to leverage its strong relationship with the National Cancer Institute to progress its MUC1 program, which is part of a collaborative research agreement [11][44] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of the Versamune HPV and pembrolizumab combination to significantly improve patient outcomes, citing encouraging clinical responses and survival data from previous trials [8][27] - The management team emphasized the importance of durability in treatment responses, noting that patients in the VERSAL-two trial had a median overall survival of 30 months compared to the standard of care's 12 months [27][28] Other Important Information - The company raised approximately $11 million through a securities purchase agreement and completed a refinancing of its debt, extending the term to 36 months [14][15] - The company plans to present updated results from the VERSAL-two study at the upcoming ASCO Annual Meeting [54] Q&A Session Summary Question: Impact of Keytruda head and neck neoadjuvant data on enrollment expectations for Phase III - Management clarified that the KEYNOTE-689 trial focused mainly on HPV negative patients and should not affect enrollment in the VERSAL-three trial, as very few HPV positive patients are eligible for surgery [22][23] Question: Insights on durability from the upcoming ASCO presentation - Management indicated that the upcoming ASCO presentation will provide additional data on durability and survival, highlighting the long-term responses observed in the VERSAL-two trial [24][27] Question: Enrollment status for the VERSAL-three trial - Management stated that enrollment details have not been publicly disclosed yet, as the activation of sites and patient screening processes are ongoing [48][49] Question: Future operating expenses expectations - Management noted that while they do not provide specific financial guidance, they expect a relatively stable trial spend going forward, with higher initial expenses typical in the early stages of a trial [51]

Endava (DAVA) Q3 2025 Earnings Call May 14, 2025 08:00 AM ET Company Participants Laurence Madsen - Manager - Investor RelationsJohn Cotterell - Chief Executive OfficerMark Thurston - Chief Financial OfficerBryan Bergin - MD - Equity ResearchTyler DuPont - Equity Research AssociateJonathan Lee - Managing Director - Equity ResearchJames Faucette - Managing Director Conference Call Participants Harry Read - Equity Research AnalystJames Friedman - Senior FinTech & IT Services Research AnalystPhani Kanumuri - A ...

Local Bounti (LOCL) Q1 2025 Earnings Call May 14, 2025 08:00 AM ET Company Participants Jeff Sonnek - Managing DirectorCraig Hurlbert - Co-Founder, Director & Executive ChairmanKathleen Valiasek - President, CEO & CFOKristen Owen - Managing Director Conference Call Participants Ben Klieve - Senior Equity Research Analyst Operator Good morning and welcome to Local Bounty's First Quarter twenty twenty five Earnings Conference Call. All participants will be in a listen only mode. After today's presentation, th ...

Sanara MedTech (SMTI) Q1 2025 Earnings Call May 14, 2025 08:00 AM ET Company Participants Ron Nixon - CEO & Executive ChairmanSeth Yon - President of CommercialSam Muppalla - CEOElizabeth Taylor - CFOYi Chen - Managing Director, Equity ResearchMatthew Park - Equity Research Associate Operator Welcome to the Sonera MedTech First Quarter of twenty twenty five Earnings Conference Call. Please note that this conference call is being recorded and a replay will be available on the Investor Relations page of the c ...

Dynatrace (DT) Q4 2025 Earnings Call May 14, 2025 08:00 AM ET Company Participants Noelle Faris - Vice President, Investor RelationsRick McConnell - Chief Executive OfficerJim Benson - Chief Financial OfficerBrent Thill - Tech Sector Leader, Software/Internet ResearchRaimo Lenschow - Managing DirectorKash Rangan - Managing DirectorSanjit Singh - Executive DirectorPinjalim Bora - Executive Director - Equity Research Conference Call Participants Patrick Colville - Lead Equity Research AnalystMatt Hedberg - Ma ...

Financial Data and Key Metrics Changes - System wide sales for Q1 fiscal 2025 reached $225.9 million, a 2.1% increase from $221.4 million in the previous year, driven by the shift in the Easter holiday and payment timing [6][23] - Same store sales grew by 70 basis points, but adjusting for the Easter shift, it would have been approximately flat [23] - Adjusted EBITDA increased by 7.2% to $18.8 million from $17.5 million, with an adjusted EBITDA margin rising to 36.5% from 33.7% [25] - Adjusted net income rose by 10.3% to $9.5 million from $8.6 million [26] Business Line Data and Key Metrics Changes - Total revenue decreased by approximately $400,000 or 90 basis points to $51.4 million, primarily due to lower retail and wholesale product revenue [24] - The company ended Q1 with 1,062 centers, representing a 1% growth year over year, with five gross openings and ten closures, resulting in five net center closures [22] Market Data and Key Metrics Changes - The company is experiencing stable trends in mature center transactions year to date, with expectations for flat to positive same store sales growth [29][82] - The macroeconomic environment remains uncertain, but the core guest base has shown resilience [81] Company Strategy and Development Direction - The company aims to focus on driving sales, improving profitability, and reigniting unit growth, emphasizing the importance of a strong marketing engine and franchisee support [9][10][19] - A more sophisticated development approach is being implemented, focusing on profitable expansion and identifying underpenetrated trade areas for future growth [18] - The company is actively exploring alternative sourcing options to mitigate tariff impacts on product costs [31][32] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the uncertain consumer backdrop and supply chain environment but remains confident in the fundamentals of the business model [7][28] - The outlook for 2025 is reiterated, with expectations for system wide sales between $940 million and $960 million, and same store sales expected to be flat to positive 2% [30][34] Other Important Information - The company has made significant progress in assembling a new executive team to execute strategic priorities [20] - The marketing strategy is being refined to better target high-value guests and improve guest engagement [12][14] Q&A Session Summary Question: Can you talk about the game plan going forward and the potential tariff impact? - Management is pleased with progress and sees stability in the business, with no material changes in promotional activity expected [41][44] - The company is actively exploring alternative sourcing options to manage tariff exposure [46][47] Question: What are you hearing from franchisees regarding center closures? - Franchisees are passionate about the brand, and the company is focused on building strong partnerships to improve profitability and minimize closures [50][52] Question: Can you provide insight into the increase in capital investment? - The increase is primarily due to inflationary pressures rather than fundamental changes in the business model [60] Question: What are the key themes for the upcoming franchise convention? - The convention will cover a full situation assessment, opportunities, and a plan to maximize potential [62] Question: How do you prioritize marketing and franchisee execution? - The primary focus is on the marketing funnel and franchisee execution, with ongoing efforts to improve guest experience and profitability [100][101] Question: What is the strategy for dealing with higher input prices due to tariffs? - The company is evaluating all options, including potential price adjustments, but aims to manage costs effectively without compromising the brand [112]

Financial Data and Key Metrics Changes - Net sales increased by 19.9% to $167.1 million in Q1 2025 compared to $139.4 million in Q1 2024 [6][14] - Gross profit rose by 18.8% to $28.6 million, with a gross margin of 17.1% [11][16] - Net income attributable to parent company shareholders decreased to $7.1 million from $8.3 million year-over-year [20][21] - Diluted income per share was $0.24, down from $0.27 in the previous year [21] Business Line Data and Key Metrics Changes - Sales of electric power steering (EPS) systems increased by 54% year-over-year to $73 million, representing approximately 43.7% of total sales [15][16] - Traditional steering products and parts saw a 2.3% increase in sales to $94.1 million [14] - The Henlong subsidiary reported a 37.5% increase in sales of traditional hydraulic steering systems [7] Market Data and Key Metrics Changes - Chinese GDP growth was 5.4% year-over-year in Q1 2025 [8] - Combined unit sales of passenger and commercial vehicles in China increased by 11.2% to 7.5 million units [8][10] - New energy vehicle unit sales grew by 47.1% year-over-year to 3.1 million units, representing 41.2% of total car sales in China [9] Company Strategy and Development Direction - The company aims to maintain a revenue guidance of $700 million for the full fiscal year 2025, based on current market conditions [23] - The strategy includes seeking more market share through competitive pricing, which has resulted in revenue growth [39] - The company is focusing on advanced gearing technologies and a diverse product portfolio to address market opportunities [14] Management Comments on Operating Environment and Future Outlook - Management noted that the Chinese economy has stabilized but still faces challenges [8] - The company anticipates maintaining a gross margin similar to Q1 2025 for the rest of the year, with slight improvements expected [39] - The impact of proposed U.S. tariffs has been minimal, with continued order flow and strategic planning for global expansion [46] Other Important Information - R&D expenses increased by 64% to $8.7 million, primarily due to advancements in EPS product development [11][18] - Operating expenses rose by 41.3%, leading to a 10.5% reduction in income from operations [12][19] - The company has begun mass production of its new R EPS product, which features advanced steering assist technologies [13] Q&A Session Summary Question: Why did R&D increase by 64% in Q1 2025? - The increase was due to heightened efforts in EPS product development, including staffing and equipment design [27][28] Question: What is the outlook for inventory levels and revenue in 2025? - Inventory increased due to advanced shipments in response to potential tariff pressures, but overall revenue is expected to maintain healthy levels [32][34] Question: What is the outlook for gross margin for the rest of 2025? - The gross margin is expected to remain similar to Q1 2025, with slight improvements anticipated [38][39] Question: What is the impact of U.S. proposed tariffs on new order flow? - The impact has been minimal, with continued order flow and proactive measures taken to manage inventory [46] Question: Update on the manufacturing of the R EPS product? - Mass production has begun, with orders from multiple OEMs including Cherry Auto and Iveco [49] Question: Update on Sentient operation and autonomous driving systems? - Significant progress has been made, with contracts from Volvo Truck and BYD, targeting substantial unit shipments for 2025 [50][52]

Financial Data and Key Metrics Changes - For Q1 2025, the company reported a net loss of approximately $8.5 million, or about $0.21 per share, compared to a net loss of $10.6 million, or $0.30 per share, in Q1 2024, reflecting improved tax benefits and lower operating expenses [12][14] - Research and development expenses decreased to $5.8 million from $6.7 million year-over-year, primarily due to lower clinical trial expenses [12] - General and administrative expenses were $3.3 million, slightly down from $3.4 million in the prior year [12] - Total operating expenses for the quarter were $9.1 million, down from approximately $10.1 million in the previous year [12] - Cash balance as of March 31, 2025, was $40 million, compared to $41.7 million as of December 31, 2024 [13] Business Line Data and Key Metrics Changes - The company is advancing its clinical programs, particularly the Versamune HPV plus pembrolizumab treatment for HPV16 positive head and neck cancer, with the initiation of the VERSAL-three registrational trial [5][8] - The VERSAL-three trial design includes approximately 350 patients and has received FDA approval [6][8] Market Data and Key Metrics Changes - The company anticipates that by the mid-2030s, HPV16 positive head and neck cancer will become the most prevalent type of head and neck cancer in the U.S. and Europe [5] - The VERSAL-three trial is the first phase three trial targeting the high-risk HPV16 population [8] Company Strategy and Development Direction - The company is focused on the potential of Versamune HPV in improving outcomes for patients with recurrent and metastatic HPV16 positive head and neck cancer [5][8] - There is a strong emphasis on collaboration with institutions like the Mayo Clinic and the National Cancer Institute to enhance research and development efforts [10][11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of the Versamune HPV and pembrolizumab combination to significantly improve patient outcomes, citing encouraging clinical response durability [7][28] - The management team highlighted the importance of maintaining long-term clinical responses, with a median overall survival of 30 months observed in the VERSAL-two trial compared to the standard of care's 12 months [28][29] Other Important Information - The company raised approximately $11 million through a securities purchase agreement and completed a refinancing of its debt, extending the term to 36 months [14] - The upcoming ASCO Annual Meeting will feature presentations on the VERSAL-two trial and other studies, which are expected to provide further insights into the company's clinical advancements [9][54] Q&A Session Summary Question: Impact of Keytruda head and neck neoadjuvant data on enrollment expectations for VERSAL-three - Management clarified that the KEYNOTE-689 trial primarily involved HPV negative patients, and thus, it should not affect enrollment in the VERSAL-three trial, which focuses on HPV positive patients [22][23] Question: Insights on durability from the upcoming ASCO presentation - Management indicated that the ASCO presentation will provide updates on the durability of responses observed in the VERSAL-two trial, emphasizing the long-term survival benefits compared to standard treatments [24][30] Question: Enrollment status for VERSAL-three and operational expenses outlook - Management stated that enrollment details have not been publicly disclosed yet, and they expect a steady recruitment state as more sites are activated [47][50]

Financial Data and Key Metrics Changes - System wide sales for Q1 2025 reached $225.9 million, a 2.1% increase from $221.4 million in Q1 2024, driven by the shift in the Easter holiday and payment timing [23][6] - Same store sales grew by 70 basis points, but adjusting for the Easter shift, it would have been approximately flat [23][6] - Adjusted EBITDA increased by 7.2% to $18.8 million from $17.5 million in the prior year, with an adjusted EBITDA margin rising to 36.5% from 33.7% [25][26] - Adjusted net income rose by 10.3% to $9.5 million from $8.6 million in the previous year [26] Business Line Data and Key Metrics Changes - Total revenue decreased by approximately $400,000 or 90 basis points to $51.4 million, primarily due to lower retail and wholesale product revenue [24] - SG&A expenses increased by $1.9 million to $15.3 million, driven by higher stock-based compensation and executive severance costs [25] - Advertising expenses decreased by $1.4 million due to the timing of spend within the fiscal year [25] Market Data and Key Metrics Changes - The company ended Q1 with 1,062 centers, representing a 1% growth year over year, with five gross openings and ten closures resulting in five net center closures [22] - The company expects 10 to 12 gross openings and 40 to 60 center closures for the year, leading to 28 to 50 net center closures [29] Company Strategy and Development Direction - The company aims to focus on driving sales, improving four wall profitability, and reigniting unit growth as critical components for revitalizing long-term growth [10][19] - A data-rich digital-first marketing engine is being developed to enhance guest engagement and drive new guest acquisition [11][12] - The company is implementing a more sophisticated development approach focused on thoughtful, profitable expansion, identifying underpenetrated trade areas for future growth [17][18] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the uncertain consumer backdrop and supply chain environment but emphasizes strong fundamentals and proactive management [7][6] - The outlook for 2025 is reiterated, assuming a stable consumer environment, with expectations for system wide sales between $940 million and $960 million [28][30] - Management is confident in their ability to manage tariff impacts and maintain guidance despite macroeconomic challenges [31][34] Other Important Information - The company has made substantial progress in assembling a team of seasoned leaders to execute strategic priorities for 2025 and beyond [19][20] - The company is actively exploring alternative sourcing options to mitigate tariff impacts on product costs [31][44] Q&A Session Summary Question: Can you talk about the game plan going forward and the potential tariff impact? - Management is pleased with progress and sees stability in the business, with no material changes in promotional activity expected [39][41] - They are actively exploring all options to manage tariff exposure, including alternative sourcing [44] Question: What are you hearing from franchisees regarding center closures? - Franchisees are passionate about the brand, but the past few years have been tough, leading to underperforming centers [48][50] Question: Can you provide insight into the cost to build and return to net unit growth? - The increase in capital investment is attributed to inflationary pressures, with a focus on optimizing costs and operations [57] Question: What are the key themes for the upcoming franchise convention? - The convention will cover a full situation assessment, opportunities, and a plan to maximize potential [60] Question: How do you prioritize marketing, franchisee execution, and other factors? - The primary focus is on the marketing funnel and franchisee execution, followed by waxer consistency and consumer value [96][98] Question: What is the performance of underperforming stores versus healthy stores? - Underperforming stores are primarily an AUV issue, with various factors contributing to their performance [65][100]

RADCOM (RDCM) Q1 2025 Earnings Call May 14, 2025 08:00 AM ET Speaker0 Ladies and gentlemen, thank you for standing by. Welcome to the Radcom Limited Results Conference Call for the First Quarter of twenty twenty five. All participants are present in listen only mode. Following management's formal presentation, instructions will be given for the question and answer session. As a reminder, this conference is being recorded and will be available for replay on the company's website at www.radcom.com later today ...